Drugs / Synthetic PIF
Synthetic PIF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02239562 | Nov 2014 → Apr 2016 | autoimmune hepatitis | Christopher O'Brien, MD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic PIF | “Additionally, synthetic PIF (PIF analog) protects against multiple immune disorders.” PMID 28704412 ↗ Jul 2017 |
| Known as | sPIF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02239562 ↗ |
| Known as | synthetic PreImplantation Factor | “synthetic PreImplantation Factor” NCT02239562 ↗ |
| Route | Subcutaneous | “Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1” NCT02239562 ↗ |